1型糖尿病青少年启用不同自动胰岛素输送系统后90天范围内时间的变化
美国单中心回顾性研究纳入428例<21岁1型糖尿病青少年,比较启用Ominpod 5(OP5)与Control IQ(CIQ)后90天范围内时间(TIR)的变化。两组90天TIR均较基线升高,OP5组升高11.8个百分点(95%CI 10.4–13.3),CIQ组升高9.8个百分点(95%CI 8.3–11.2),组间无显著差异(P=.08)。作者认为两种系统90天TIR无临床显著差异。
要点
- 两组90天TIR均较基线显著升高(P<.001),OP5组升高11.8个百分点,CIQ组升高9.8个百分点。
- 90天TIR组间差异未达统计学显著(P=.08)。
- 按基线TIR分层后,90天TIR组间仍无差异。
核心结论
- 作者认为,1型糖尿病青少年启用两种最常用自动胰岛素输送系统后90天TIR无临床显著差异。
- 作者建议,患者偏好与共同决策应继续指导自动胰岛素输送系统的选择。
研究设计与样本
- 单中心、回顾性研究,纳入2020年1月至2023年12月期间启用OP5或CIQ的<21岁1型糖尿病青少年,要求连续葡萄糖监测(CGM)活跃时间≥70%。
- 共纳入428例,OP5组与CIQ组各214例(50%)。
- 获取14天基线及90天CGM与自动胰岛素输送数据,采用多元线性回归模型评估90天TIR变化,并按基线TIR类别进行亚组分析。
主要发现
- OP5组1型糖尿病病程短于CIQ组(1.6年 vs 5.5年,P<.001),且更多由每日多次注射转换而来(76.1% vs 20.1%,P<.001)。
- 基线TIR两组相似(OP5组51.6% vs CIQ组53.1%,P=.70)。
- 90天TIR两组均升高(P<.001):OP5组升高11.8个百分点(95%CI 10.4–13.3),CIQ组升高9.8个百分点(95%CI 8.3–11.2),组间差异未达统计学显著(P=.08)。
- 按基线TIR类别分层,90天TIR组间无差异。
临床怎么用
- 作者建议,患者偏好与共同决策应继续指导自动胰岛素输送系统的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Glycemic outcomes in youth with type 1 diabetes (T1D) in the United States using the 2 most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ), have not been compared. OBJECTIVE: We performed the first head-to-head analysis of changes in glycemic metrics among youth initiating AID. METHODS: This single-center, retrospective study included youth < 21 years with T1D, who started OP5 or CIQ between January 2020 and December 2023, and had ≥ 70% continuous glucose monitoring (CGM) active time. We obtained 14-day baseline and 90-day CGM and AID data. A multiple linear regression model assessed for changes in 90-day time in range (TIR) according to AID system, adjusting for covariates. Subanalyses were conducted according to baseline TIR categories. RESULTS: Among the 428 included youth, there were 214 (50%) in each AID group. OP5 users had a shorter T1D duration (1.6 vs 5.5 years, P < .001) and were more likely to have transitioned from multiple daily injections (76.1% vs 20.1%, P < .001). Baseline TIR was similar between groups (OP5 51.6% vs CIQ 53.1%, P = .70). 90-day TIR increased in both groups (P < .001), rising by 11.8 percentage points (95% CI [10.4, 13.3]) in OP5 users and 9.8 percentage points (95% CI [8.3, 11.2]) in CIQ users, without any significant between-group differences (P = .08). There were no between-group differences in 90-day TIR according to categorical baseline TIR. CONCLUSION: There are no clinically significant differences in 90-day TIR among youth with T1D initiating the 2 most commonly used AID systems. Patient preference and shared decision making should continue to guide the selection of AID systems.
引用
- Gera S, Rearson A, Baker G, et al. Changes in 90-Day Time in Range Among Youth With Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems. J Clin Endocrinol Metab. 2025. PMID: 39813114. doi:10.1210/clinem/dgaf006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。